Fate of the Fc fusion protein aflibercept in retinal endothelial cells: competition of recycling and degradation

Heidrun L. Deissler 1 · Gerhard K. Lang 1 · Gabriele E. Lang 1

Received: 19 January 2018 / Revised: 1 October 2018 / Accepted: 16 October 2018 / Published online: 26 October 2018
© The Author(s) 2018

Abstract

Purpose Intravitreal injection of the VEGF-binding protein aflibercept is widely used to treat various ocular diseases. In vitro, immortalized bovine retinal endothelial cells (iBREC) take up and transport aflibercept through the cell layer in a serum-dependent manner, likely mediated through the neonatal Fc receptor (FcRn), but degradation of the Fc domain-containing protein might be a competing intracellular process. Therefore, aflibercept’s associations with proteins either involved in FcRn-mediated transport or in the lysosomal pathway were studied.

Methods Confluent iBREC pre-cultivated with or without FBS were exposed for 4 h to in vivo achievable 250 μg/ml aflibercept, before cells were harvested for immunofluorescence staining or preparation of protein extracts. Intracellular localization of aflibercept and putative co-localizations with proteins involved in transport of IgG/FcRn complexes, i.e., endosomal Rab4 and Rab11, components of the cytoskeleton, motor proteins, or with marker proteins characteristic of multivesicular bodies or lysosomes were assessed by co-immunofluorescence stainings. Amounts of expressed endogenous proteins and of internalized aflibercept were determined by Western blot analyses.

Results Aflibercept-specific perinuclear staining overlapped with that of the motor protein dynein whereas double staining with an anti-kinesin antibody resulted in a patchy pattern. In addition, aflibercept was typically present close to microtubules and often co-localized with α-tubulin. Rab4 and Rab11 stainings partly overlapped with the perinuclear staining of aflibercept whereas co-localization with Rab7 (in late endosomes/lysosomes) was only rarely seen. Interestingly, aflibercept but not the IgG bevacizumab broadly co-localized with the cation-independent mannose 6-phosphate receptor characteristic of multivesicular endosomes. In accordance with partial degradation beside transcytosis, the amount of intracellular aflibercept increased when cells were treated with protease inhibitors MG-132 or MG-101. Serum-deprived iBREC expressed less Rab11 and dynein but slightly more Rab4.

Conclusion After uptake by iBREC, aflibercept is present in organelles associated with FcRn-mediated transport, but part of the protein is subject to degradation. Transport inhibition of aflibercept during cultivation without FBS is likely a consequence of an attenuated exocytosis due to decreased expression of Rab11.

Keywords Retinal endothelial cells · Aflibercept · Fc fusion protein · IgG · Neonatal Fc receptor · Recycling · Degradation

Introduction

Aflibercept, a recombinant protein binding to members of the family of vascular endothelial growth factors (VEGFs), is widely used to treat various ocular diseases associated with an elevated VEGF expression [1, 2]. After intravitreal injection into the mammalian eye, aflibercept, which contains an Fc (fragment crystallizable) domain, was detected in ocular structures including retinal vessels and the retinal pigment epithelium (RPE), implying at least partial clearance of aflibercept via the posterior route [3–5]. Accordingly, retinal endothelial cells (REC) or cells of the RPE take up aflibercept in vitro, and transcellular transport through these types of cells was observed [6–8]. A carrier protein likely involved in shuttling Ig and other Fc-containing polypeptides is the neonatal Fc receptor/transporter (FcRn), which indeed is expressed in various parts of the eye including the retinal endothelium and...
cultivated REC [9–12]. In human dermal microvascular endothelial cells (HMEC), the FcRn is present in early endosomes characterized by presence of early endosome antigen 1 (EEA1) and the small Ras-like GTPase 4 (Rab4) [13–15]. In these organelles, it binds at low pH to IgG that has been internalized by pinocytosis, after which the complex is separated from unbound IgG and other proteins in sorting endosomes (positive for Rab4 and Rab11) [9, 13–15]. FcRn-bound IgG is then transported by recycling exosomes (positive for Rab11 but not for Rab4) to be released at the cell surface, thereby avoiding subsequent intracellular degradation in lysosomes [13, 15, 16]. In contrast, unbound IgG or other proteins destined to be eventually degraded in lysosomes, could be detected at an earlier stage mainly in multivesicular endosomes characterized by the presence of the cation-independent mannose 6-phosphate receptor (CI-M6PR) [17].

Because aflibercept is a protein with an Fc terminus of a human IgG1, a role of the FcRn in its transport through REC is a plausible assumption, recently supported by our investigations with immortalized bovine REC (iBREC). Through a monolayer of these cells, aflibercept is transported via an FcRn-mediated process, which was also observed in similar experiments with the VEGF-A-binding humanized IgG bevacizumab [7, 12]. However, aflibercept as an Fc fusion protein has distinct properties different from those of a classical IgG and this might result in at least partly altered mechanisms of intra-REC transport. Fc fusion proteins indeed tend to have a shorter serum half-life compared with IgG often due to a lower binding affinity to the FcRn [18, 19]. Therefore, we investigated whether aflibercept taken up by iBREC was co-localized with proteins involved in an FcRn-mediated transport or those indicative of the lysosomal route. The human and bovine homologs of proteins likely participating in the investigated processes, i.e., FcRn, Ras-like GTPases, CI-M6PR, and others, are highly conserved or even identical, allowing experiments based on the well-established model of iBREC and double immunofluorescence staining with available specific antibodies [20, 21]. It was also directly confirmed in several studies that human IgG is efficiently bound, transported, and released by bovine FcRn in vivo and in vitro [22–24].

**Material and methods**

**Aflibercept and antibodies**

Bayer Vital GmbH (Leverkusen, Germany) kindly provided Eylea (40 mg/ml aflibercept in 10 mM sodium phosphate, 40 mM NaCl, 0.03% polysorbate 20, 5% sucrose, pH 6.2) [1, 2]. The humanized anti-VEGF antibody bevacizumab (Avastin; 25 mg/ml in 50 mM sodium phosphate, 6% α,α-[trehalose dihydrate, 0.04% polysorbate 20, pH 6.2; Roche Pharma, Grenzach-Wyhlen, Germany) was repackaged at the pharmacy of the University Hospital Ulm and provided in syringes, which were stored at 4 °C not longer than 4 weeks [25]. Tables 1 and 2 provide all relevant information on primary and secondary antibodies used for immunofluorescence staining or Western blot analyses.

| Table 1 Primary antibodies used |
|-------------------------------|
| **Target** | **Host** | **Type** | **Source** | **Working concentrations** |
| AcTin | Mouse | Monoclonal | Clone AC-40, Abcam (Cambridge, UK), ab11003 | WB, 500 ng/ml |
| Caveolin-1 | Rabbit | Polyclonal | Abcam, ab2910 | WB, 20 ng/ml; IF, 1 μg/ml |
| CI-M6PR/IGF2-R | Mouse | Monoclonal | Thermo Fisher Scientific (Langenselbold, Germany), MA1-066 | IF, 2 μg/ml |
| Claudin-1 | Rabbit | Polyclonal | JAY.8, Thermo Fisher Scientific, 51-9000 | WB, 1 μg/ml |
| Claudin-5 | Rabbit | Polyclonal | Thermo Fisher Scientific, 34-1600 | WB, 100 ng/ml |
| Dynein | Mouse | Monoclonal | Clone 74.1, Abcam, ab23905 | WB, 1 μg/ml; IF, 10 μg/ml |
| EEA1 | Rabbit | Polyclonal | Abcam, ab137403 | WB, 70 ng/ml; IF, 20 μg/ml |
| FcRn (large chain) | Rabbit | Polyclonal | Bio-technne (Wiesbaden, Germany), NBP1-89127 | WB, 3 μg/ml |
| Kinesin (heavy chain) | Mouse | Monoclonal | Clone SUK-4, Abcam, ab28060 | IF, 1.3 μg/ml |
| Rab4 | Rabbit | Polyclonal | Thermo Fisher Scientific, PA-912 | WB, 1:500; IF, 1:75 |
| Rab7 | Rabbit | Polyclonal | Thermo Fisher Scientific, PA5-22959 | IF, 1:100 |
| Rab11a, Rab11b, Rab11c | Goat | Polyclonal | Siegen Antibodies (Carcavelos, Portugal), AB3035 | WB, 1.5 μg/ml |
| Rab11 | Rabbit | Polyclonal | Abcam, ab3612 | IF, 5 μg/ml |
| α-Tubulin | Mouse | Monoclonal | Clone DM1A, Abcam, ab7291 | WB, 200 ng/ml; IF, 1 μg/ml |
| Vimentin | Mouse | Monoclonal | Clone RV202, Abcam, ab9878 | WB, 70 ng/ml; IF, 1 μg/ml |

*WB*, Western blot analyses; *IF*, immunofluorescence stainings; *CI-M6PR/IGF-2R*, cation-independent mannose 6-phosphate receptor/insulin-like growth factor 2 receptor; *EEA1*, early endosomal antigen 1
**Treatement of iBREC with effectors**

Generation and characterization of telomerase-immortalized microvascular endothelial cells from bovine retina (iBREC), which even after extended cultivation show the cobblestone-like morphology typical of EC-forming retinal capillaries, were comprehensively described [12, 21, 26]. Cells were cultivated on fibronectin-coated (Corning, Amsterdam, The Netherlands) surfaces in Endothelial Cell Growth Medium MV (ECGM; Promocell, Heidelberg, Germany) containing 1 g/l glucose, 0.4% Endothelial Cell Growth Supplement/H, 90 μg/ml heparin, 10 ng/ml human epidermal growth factor (hEGF), 100 nM 11β-hydroxycortisone, and 5% fetal bovine serum (FBS) as described previously [12, 21]. Cells were used from passages 25 to 60 counting from the stage of primary culture for which we had confirmed stable expression of marker proteins typical for EC (e.g., von Willebrand factor, tight-junction-proteins claudin-1 and claudin-5) and proteins under investigation [6, 7, 12, 21]. Pericytes or other cells expressing α-smooth muscle actin are not present in iBREC cultures [21]. To ensure authenticity and optimal conditions of iBREC in the experiments, we routinely recorded their characteristic proliferation profile by electric cell-substrate impedance measurements using the microelectronic biosensor system for cell-based assays xCELLigence RTCA DP (Acea, OLS, Bremen, Germany) [27]. All experiments—repeated at least twice—were performed with confluent monolayers of iBREC formed after cultivation for 4 days. In control experiments, we processed the cells identically in medium only lacking the effector(s) investigated.

Prior to investigations with confluent iBREC, ECGM was replaced with SHM (same medium as ECGM but lacking hEGF) or—in to study the effect of FBS—with SFM (same as SHM but without FBS) for 1 day. Aflibercept (or bevacizumab) was added for additional 4 h before cells were harvested for preparation and analyses of subcellular fractions or fixed for immunofluorescence staining (see below). VEGF-binding proteins were used at a final concentration of 250 μg/ml, resembling the in vivo situation after intravitreal injection [2, 6, 7, 12].

To assess the effects of the protease inhibitors MG-101 or MG-132 (Selleckchem, Absolute Diagnostics, Munich, Germany) on barrier stability, confluent iBREC grown on gold electrodes (E-Plates 16 PET, Acea) were treated with these substances at concentrations ranging from 20 nM to 5 μM or to 20 μM, respectively [27–30]. The cell index as a measure of permeability was recorded every 5 min for at least 24 h [27].

**Preparation of protein extracts**

Fresh or frozen cell pellets were subjected to subsequently carried out extraction steps with different buffers (ProteoExtract Subcellular Proteome Extraction Kit, Merck Millipore, Darmstadt, Germany), resulting in subcellular fractions containing proteins localized in the cytoplasm, in membranes/organelles, or components of the cytoskeleton [7, 12]. Protein concentrations in the samples were determined using the Pierce Thermo Scientific BCA Protein Assay Kit according to the manufacturers’ instructions.

**Western blot analyses and imaging**

For Western blot analyses, proteins (3 μg/lane) were separated by SDS-polyacrylamide electrophoresis under reducing conditions followed by electroblootting as described in detail previously [7, 27]. Appropriate IgG-horseradish peroxidase conjugates (Table 2) and the chemiluminescence kit Pierce ECL Plus Western Blotting Substrate (Thermo Fisher Scientific) were used to detect antigen-bound primary antibodies. As previously observed, the horseradish peroxidase conjugate used to detect human IgG gave rise to an additional unspecific signal when isolated cytoskeleton proteins were analyzed [6, 7, 12]. Chemiluminescence signals from the so processed membranes were directly scanned with the imaging system Fusion Pulse TS (Vilbert Lourmat, VWR, Darmstadt, Germany) resulting in images with bright specific bands contrasting with a dark background. To quantify the signals, peak volumes of the corresponding bands (≥ 4 replicates) determined with EvolutionCapt software (Vilbert Lourmat) were standardized in relation to those obtained from similarly processed control cells.
Double immunofluorescence staining

Confluent iBREC were cultivated on fibronectin-coated two-chamber slides (x-well PCA Tissue Culture Chambers; Sarstedt, Nuembrecht, Germany) and exposed to aflibercept or bevacizumab for 4 h as described above [7, 12]. After methanol-fixation (10 min at −20 °C), cells were permeabilized for 10 min in 0.25% Nonidet P-40 substitute (Roche, Mannheim, Germany) diluted in PBS without Ca²⁺/Mg²⁺ ions (PBSd). After incubation of the slides in blocking solution (10% ImmunoBlock, Roth, Karlsruhe, Germany) for 60 min at room temperature, they were treated for 30 min with AlexaFluor594-conjugated antibodies binding to human IgG to detect aflibercept or bevacizumab. Slides were then exposed to primary antibodies recognizing endogenous proteins of interest for 1 h at room temperature, and subsequently to appropriate AlexaFluor488-conjugated goat F(ab')2 fragments for 30 min. Primary and secondary antibodies were always diluted in 1% ImmunoBlock/PBSd. For examination by fluorescence microscopy (DM4000B, FW4000, Leica, Wetzlar, Germany), cells were embedded in ProLong Gold/Diamond Antifade Mountant with DAPI (Thermo Fisher Scientific) [7, 12, 27].

Transcytosis assays

Transcytosis assays were performed as published to assess transport of aflibercept through a confluent iBREC monolayer cultivated on membrane inserts (4.7 cm², pore size 0.4 μm; Corning) from the lower to the upper chamber [7, 12]. After incubating iBREC for 1 day in SHM or SFM, aflibercept (final concentration, 250 μg/ml) was placed in the bottom chamber and samples were then taken from the upper chamber at indicated time points. Presence of aflibercept in these samples was assessed by Western blot analyses and peak volumes of the corresponding bands (four replicates) determined with EvolutionCapt software (Vilbert Lourmat) were normalized in relation to those obtained from 1 ng aflibercept.

Statistical analyses

Mann-Whitney tests or one-way analyses of variance (ANOVA) followed by Tukey’s test were used to compare differing groups of quantified antigen-specific signals from Western blot analyses (Graph Pad Prism 6; Graph Pad Software, San Diego, USA), and differences resulting in p values below 0.05 were considered significant. Means and standard deviations were provided as numbers or in scatter plots.

Results

Aflibercept was present in organelles associated with FcRn-mediated transport and in multivesicular endosomes within 4 h after uptake

To determine aflibercept’s intracellular localization, we performed double-immunofluorescence stainings of iBREC treated with pharmacologically achievable 250 μg/ml of the therapeutic protein for 4 h. Then aflibercept had been taken up and transported through an iBREC monolayer, and substantial amounts of the recombinant protein remained in the cells resulting in a pronounced perinuclear staining in addition to a faint and diffuse overall intracellular staining [6, 7]. Direct targeting the FcRn was not possible because commercially available antibodies failed to give specific signals, but the assessed proteins were reported to be crucially involved either in the transport of FcRn/IgG-complexes or in lysosomal processes in endothelial cells (EC) or other cell types [7, 11–17, 31–34].

Microtubule are involved in the transport of IgG/FcRn complexes in various cell types [31–33]. Accordingly, aflibercept co-localized with the microtubule component α-tubulin mainly in the perinuclear region close to or identical with the microtubule organization center (Fig. 1a, yellow arrows) but also close to the tubulin fibers in the periphery of the cells (Fig. 1a, blue arrows). Members of the motor protein family of dyneins transport cargo along microtubules from the plasma membrane to the cell body whereas kinesins are involved in similar transport in the opposite direction [33]. Interestingly, aflibercept-specific staining overlapped with that of the intermediate chain (IC74) of dynein in the perinuclear region (Fig. 1b) whereas signals specific for the heavy chain (HC) of kinesin were rather patchy with only a few overlaps (Fig. 1c, yellow arrows or arrowheads). Co-localization of aflibercept with other cytoskeletal proteins, e.g., actin or vimentin, or with caveolin-1—a component of caveolae—was not observed. In HMEC, early endosomes (→Rab4, EE1A), sorting endosomes (→Rab4, Rab11), and recycling exosomes (→Rab11) contain the FcRn or FcRn/IgG complexes [14, 15]. In accordance with our previous observation that the perinuclear staining of aflibercept often overlapped with that of EEA1, aflibercept was also co-localized in the perinuclear region with signals specific for Rab4 (Fig. 2a) [7]. In addition, stainings of aflibercept and Rab4 overlapped in the periphery of the cells. In the same subcellular regions, we also observed partial co-localization of aflibercept with Rab11 (Fig. 2b).

Internalized aflibercept might be degraded, and proteins destined for degradation were detected in multivesicular endosomes, characteristically containing CI-M6PR involved in the transport of hydrolases from the trans-Golgi network to lysosomes [17]. Remarkably, the immunofluorescence
stainings of aflibercept and CI-M6PR observed in the cells’ perinuclear regions widely overlapped (Fig. 3a). Co-localization of aflibercept with Rab7, a marker of late endosomes and lysosomes in EC, was seen sporadically and then as patchy signals rather than mixed colors (Fig. 3b) [34]. To rule out that presence of aflibercept in multivesicular endosomes might be the unlikely result of species incompatibility due to the interaction between the human Fc portion and bovine FcRn, we performed similar experiments with the VEGF-binding antibody bevacizumab also containing a human Fc terminus. As shown in Fig. 4 (yellow arrowheads or arrows), the immunofluorescence stainings specific for CI-M6PR and bevacizumab barely overlapped.

Inhibition of proteasomal and lysosomal proteases increased the amount of intracellular aflibercept

Our data support the hypothesis that the internalized aflibercept is transported through an iBREC monolayer in complex with FcRn, but part of the recombinant protein may be degraded. The cysteine protease inhibitor MG-101 counteracts the activity of lysosomal cathepsins L and B at a concentration of 20 nM or that of the non-lysosomal calpains I and II at 500 nM, respectively [28, 29]. Exposure of iBREC to either effective concentration of MG-101 together with aflibercept for 4 h resulted in a slight but significant increase of aflibercept isolated collectively with proteins from membranes and organelles (Fig. 5a).
Because most of the intracellular protein destined to be degraded enters the ubiquitin-proteasome pathway, we pre-treated iBREC with 20 nM of the inhibitor MG-132 of proteasomal proteases, before aflibercept was added to the cells for 4 h [30]. Western blot analyses of proteins subsequently isolated from the membranes/organelles and the cytoskeleton revealed that more aflibercept accumulated during protease inhibition (Fig. 5b). As was to be expected, the amounts of endogenous proteins actin and claudin-5 were higher in samples isolated from cells treated with the inhibitors MG-101 or MG-132, confirming general inhibition of protein degradation pathways under these conditions (Fig. 5c, d). Higher concentrations of MG-101 or MG-132 could not be used because they resulted in barrier dysfunction and death of iBREC as recognized by cell index measurements.

Serum depletion resulted in decreased expression of dynein and Rab11

Aflibercept’s transport through an iBREC monolayer was considerably slower when cells were cultivated without FBS and this coincided with a significantly increased amount of the recombinant protein retained in the cells (Fig. 6a, b) [7]. We also determined the cell index as a measure of iBREC permeability and found that it was high and in the same range when iBREC were cultivated with or without FBS. This confirms the presence of a stable barrier preventing paracellular transport and allowing for transcellular transport only. Based on the assumption that aflibercept’s intracellular transport could be restricted as a consequence of a changed expression of involved proteins under these conditions, we analyzed their presence in iBREC.
treated for 4 h with the Fc fusion protein after having been cultivated with or without FBS for 1 day. Western blot analyses of proteins from the cytoplasm, membranes, or organelles and the cytoskeleton showed that presence of aflibercept did not significantly affect the levels of investigated proteins at either condition. Reduced expression of the FcRn after cultivation of iBREC under serum-free conditions was not due to a general decline in protein expression as some proteins investigated were not changed and others were even expressed significantly stronger, e.g., tight junction-proteins claudin-1 and claudin-5 (Fig. 6b). Interestingly, the levels of Rab11 and dynein were also lower whereas that of Rab4 was higher after cultivation of iBREC without FBS (Fig. 6b). In addition, cultivation conditions resulted in changes of the subcellular localization of Rab4 and to a lesser extent of Rab11. Both proteins were more focused in the perinuclear region in cells cultivated without serum and overlapping of the perinuclear stainings of Rab4 and aflibercept was then slightly more pronounced.

**Discussion**

After its uptake by REC, aflibercept can be transported actively through the intracellular space but before its release from the cell surface at either side of the EC layer, it might enter the degradation pathway. That aflibercept has an Fc terminus suggests involvement of the FcRn in its transport and protection from proteolysis. To further elucidate aflibercept’s fate inside iBREC, we performed double immunofluorescence stainings with marker proteins either associated with an FcRn-mediated transport (EEA1, Rab4, Rab11) or with the lysosomal pathway in EC (CI-M6PR, Rab7) [13–17, 34]. We also included proteins of the cytoskeleton (α-tubulin, actin, vimentin) as well as motor proteins (dynein, kinesin) in our analyses because these might play a role in FcRn-mediated transport along microtubules [31–33]. Obtained data on potential co-localization help to reveal the fate of internalized aflibercept although these marker proteins do not specify a single...
Although immunofluorescence stainings result in fixed images showing the situation at one time point, they have the advantage over live cell imaging that normal conditions rather than overexpressed recombinant proteins modified with fluorescence tags are analyzed. We chose to investigate aflibercept’s localization in iBREC after its uptake in the absence of VEGF-A, because the tight barrier formed by the cells under these conditions only allowed transcellular transport without additional paracellular flow.

Aflibercept staining overlapped with or was close to that of α-tubulin, suggesting an active transport along the microtubules. This assumption is supported by the also observed colocalization of aflibercept and the dynein intermediate chain, which is part of the dynein motor protein complex carrying cargo from the plasma membrane to the cell body. Co-localization of aflibercept with Rab4 and Rab11 as well as with CI-M6PR, evident after 4 h of exposure, pointed to the vesicular containers in which the protein is transported. Presence of aflibercept in vesicles containing Rab4 and/or Rab11 is in accordance with previously observed localization in EEA1-presenting early endosomes and supports the hypothesis that the FcRn plays an important role in its transcellular transport [7]. Remarkably, aflibercept also seemed to be present in multivesicular endosomes of HepG2 cells or of epithelial cells of the rat intestine contain the FcRn, it was not detected in such vesicles of HMEC [13, 32, 35]. However, a modified IgG not able to bind to the FcRn remained in sorting endosomes in HMEC, which then matured to multivesicular endosomes [13]. From this observation and our results, we conclude that unbound aflibercept molecules not interacting with the human Fc terminus of aflibercept and the bovine FcRn efficiently transports human IgG through cells [7, 12, 22–24]. Accordingly, the humanized VEGF-binding IgG bevacizumab was only rarely detected in multivesicular endosomes in iBREC (see Fig. 4).

An increased amount of aflibercept internalized by iBREC as a consequence of general inhibition of lysosomal and proteasomal proteases showed that at least part of the Fc fusion protein is indeed degraded. The observed partial overlap of aflibercept and Rab7 stainings supports this hypothesis as appearance of Rab7 indicates maturing of sorting endosomes to (Rab7⁺) late endosomes, which transfer proteins destined for degradation to lysosomes by tubule-mediated processes [36]. Aflibercept’s entering of a pathway leading to lysosomal degradation is in accordance with the reported lower serum half-lives of other Fc fusion proteins compared with...
monoclonal antibodies, likely caused by lower affinity to the FcRn [18]. A serum half-life of aflibercept significantly lower than that of bevacizumab was also confirmed by experiments in which the proteins were administered to monkey eyes by intravitreal injection [19]. The intracellular stability of the VEGF-A-binding Fab fragment ranibizumab taken up by iBREC is even lower than that of aflibercept [37]. This might be due to the lack of an Fc terminus necessary for binding by the FcRn which is protective against intracellular proteolysis. Accordingly, a lower serum half-life after intravitreal injection was also observed [19].

The assumption that FcRn, Rab11, and Rab4, and dynein all play important roles in aflibercept’s transcellular transport is further supported by our observation that their expression or localization significantly changed when iBREC had been cultivated without FBS to slow down the transport process. Under all conditions investigated, iBREC established a strong barrier as confirmed by a high cell index, thereby allowing only transport through the cell layer. When iBREC were cultivated without FBS, the lower expression of FcRn, Rab11, and dynein was accompanied by an increased expression of other proteins including Rab4, and the accumulation of Rab4, Rab11, and EEA1 as well as aflibercept in the perinuclear region [7]. Interestingly, in HMEC sorting of an FcRn-IgG complex away from unbound IgG takes place in Rab4+/Rab11− recycling exosomes which mature to Rab4−/Rab11+ recycling exosomes [15]. Considering these observations, decreased transport and accumulation of aflibercept in serum-deprived iBREC might be caused by shortage of Rab11+ recycling exosomes leading to attenuated exocytosis.

Studying the intracellular fate of IgG or related proteins like aflibercept in REC is of considerable importance because after their therapeutic intravitreal injection they quickly reach the pericytes and endothelial cells of retinal vessels. This was demonstrated for aflibercept, bevacizumab and Fc fragments, detected in retinal vessels 1 to 2 days after their intravitreal
injection into the eyes of rodents and monkeys \[3, 38–41\]. The role of the Fc domain has been emphasized by showing that a VEGF trap derivative, which instead of the Fc terminus contains a dimerized coiled-coil domain, has an increased half-life after intravitreal injection into the rabbit eye compared with the normal VEGF trap with an Fc region \[4\]. Together with the observation that after intravitreal injection bevacizumab was present in REC of wild-type mice but not in those of FcRn\(^{−/−}\) mice, these findings strongly support the hypothesis that the Fc domain primarily destines the fate of an intravitreally injected protein and that the FcRn plays a crucial role in this process \[39\]. An FcRn-dependent transport of aflibercept through cells of the RPE was also observed \[8\]. In these cells, aflibercept is co-localized with the motor protein myosin 7a and with proteins of the cytoskeleton (→ actin), indicating a similar though not identical behavior of the Fc fusion protein in the two different cell types forming the outer and inner blood retina barrier.

Summarizing, our results presented here are in accordance with the concept that aflibercept is transported through the intracellular space of REC in a process likely mediated by the FcRn as depicted in Fig. 7. Our previous findings that inhibition of the interaction between aflibercept and FcRn significantly slows down its transcellular transport also strongly support this hypothesis \[7\]. However, at least a fraction of the amount of internalized protein is subject to degradation, indicating that in detail the behavior of the Fc fusion protein inside REC is similar to though not identical with that of an IgG.

Fig. 7 Cartoon proposing the fate of aflibercept after its uptake by iBREC. Within a few hours of exposure, aflibercept is distributed to EEA1\(^{+}\) early endosomes, endosomes positive for Rab4 and/or Rab11, and CI-M6PR\(^{+}\) multivesicular endosomes. This is in accordance with an FcRn-mediated transport of aflibercept through the intracellular space (light blue arrow), resulting in recycling of the Fc fusion protein at the surface of the cell. However, at least part of this protein is subject to degradation as indicated by our results on the effects of inhibitors of lysosomal or proteasomal proteases. Tight junctions closing the intercellular space prevent alternative paracellular transition (dark blue arrow) of the large aflibercept molecules.

Acknowledgements The authors thank Edith Glass, Nadine Gubernath, Anita Ruepp, and Sarah Scislowski for expert technical assistance and Bayer Vital GmbH, Germany for a generous gift of aflibercept. The authors are grateful to Helmut Deissler, HD/U Ulm, Germany for his advice and for supporting the preparation of the manuscript.

Funding This study was supported through a research grant by Bayer Vital GmbH, Germany to Heidrun L. Deissler. The funding source did not have any influence on study design, data analyses and interpretation, writing of the manuscript, and decision on publishing.

Compliance with ethical standards

Conflict of interest Heidrun L. Deissler has received funding from Novartis Pharma GmbH, Bayer Vital GmbH, and lecture fees from Bayer Vital GmbH. Gerhard K. Lang has received honoraria from Bayer Vital GmbH. Gabriele E. Lang has received funding from Novartis Pharma GmbH, Bayer Vital GmbH, Boehringer Ingelheim Pharma, Allergan, and Alcon Pharma GmbH and has received honoraria as a consultant from Boehringer Ingelheim Pharma and as a consultant and speaker from Novartis Pharma GmbH, Carl Zeiss Meditec, Alimera Sciences, and Bayer Vital GmbH.

Ethical approval This article does not contain any studies with human participants or animals performed by any of the authors.

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
References

1. Holash J, Davis S, Papadopulos N et al (2002) VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci U S A 99:11393–11398. https://doi.org/10.1073/pnas.172592999
2. Do DV, Nguyen QD, Boyer D et al (2012) One-year outcomes of the DAVINCI study of VEGF Trap-eye in eyes with diabetic macular edema. Ophthalmology 119:1658–1665. https://doi.org/10.1016/j.ophtha.2012.02.010
3. Julien S, Biesemeier A, Taubitz T, Schraermeyer U (2014) Different effects of intravitreally injected ranibizumab and aflibercept on retinal and choroidal tissues of monkey eyes. Br J Ophthalmol 98:813–825. https://doi.org/10.1136/bjo.2013-304019
4. Joo K, Park SJ, Choi Y et al (2017) Role of the Fc region in the vitreous half-life of anti-VEGF drugs. Invest Ophthalmol Vis Sci 58:4261–4267. https://doi.org/10.1167/iovs.17-21813
5. del Amo EM, Rimpela A-K, Heikkinen E et al (2017) Pharmacokinetic aspects of retinal drug delivery. Prog Retin Eye Res 57:134–185. https://doi.org/10.1016/j.preteyeres.2016.12.001
6. Deissler HL, Lang GK, Lang GE (2014) Capacity of aflibercept to counteract VEGF-stimulated abnormal behavior of retinal microvascular endothelial cells. Exp Eye Res 122:20–31. https://doi.org/10.1016/j.exer.2014.02.024
7. Deissler HL, Lang GK, Lang GE (2017) Neonatal Fc receptor FcRn is involved in intracellular transport of the Fc fusion protein aflibercept and its transition through retinal endothelial cells. Exp Eye Res 154:39–46. https://doi.org/10.1016/j.exer.2016.11.007
8. Dithmer M, Hattermann K, Pomarius P et al (2016) The role of Fc receptors in the uptake and transport of therapeutic antibodies in the retinal pigment epithelium. Exp Eye Res 145:187–205. https://doi.org/10.1016/j.exer.2015.12.013
9. Junghans RP, Anderson CL (1996) The protection receptor for IgG catabolism is the β2-microglobulin-containing neonatal intestinal transport receptor. Proc Natl Acad Sci U S A 93:5512–5516
10. Kim H, Fariss RN, Zhang C et al (2008) Mapping of the neonatal Fc receptor in the rodent eye. Invest Ophthalmol Vis Sci 49:2025–2029. https://doi.org/10.1167/iovs.07-0871
11. Powner MB, McKenzie JA, Christianson GJ et al (2014) Expression of neonatal Fc receptor in the eye. Invest Ophthalmol Vis Sci 55:1607–1615. https://doi.org/10.1167/iovs.13-12574
12. Deissler HL, Lang GK, Lang GE (2016) Internalization of bevacizumab by retinal endothelial cells and its intracellular fate: evidence for an involvement of the neonatal Fc receptor. Exp Eye Res 143:49–59. https://doi.org/10.1016/j.exer.2015.10.007
13. Ober RJ, Martinez C, Vaccaro C et al (2004) Imaging of iBREC: novel hTERT-immortalized bovine retinal endothelial cells. Invest Ophthalmol Vis Sci 45:1615. https://doi.org/10.1167/iovs.13-12574
14. Ober RJ, Martinez C, Vaccaro C et al (2004) Exocytosis of IgG as evidenced for an involvement of the neonatal Fc receptor. Exp Eye Res 122:20–31. https://doi.org/10.1016/j.exer.2014.02.024
15. Deissler HL, Lang GK, Lang GE (2014) Capacity of aflibercept to counteract VEGF-stimulated abnormal behavior of retinal microvascular endothelial cells. Exp Eye Res 122:20–31. https://doi.org/10.1016/j.exer.2014.02.024
16. Ober RJ, Martinez C, Vaccaro C et al (2004) Exocytosis of IgG as evidenced for an involvement of the neonatal Fc receptor. Exp Eye Res 122:20–31. https://doi.org/10.1016/j.exer.2014.02.024
35. D’Hooghe L, Chalmers AD, Heywood S, Whitley P (2017) Cell surface dynamics and cellular distribution of endogenous FcRn. PLoS One 12:e0182695. https://doi.org/10.1371/journal.pone.0182695

36. Gan Z, Ram S, Vaccaro C et al (2009) Analyses of the recycling receptor, FcRn, in live cells reveal novel pathways for lysosomal delivery. Traffic 10:600–614. https://doi.org/10.1111/j.1600-0854.2009.00887

37. Deissler HL, Deissler H, Lang GE (2012) Actions of bevacizumab and ranibizumab on microvascular retinal endothelial cells: similarities and differences. Br J Ophthalmol 96:1023–1028. https://doi.org/10.1136/bjophthalmol-2012-301677

38. Heiduschka P, Fietz H, Hofmeister S et al (2007) Penetration of bevacizumab through the retina after intravitreal injection in the monkey. Invest Ophthalmol Vis Sci 48:2814–2823

39. Kim H, Robinson SB, Csaky KG (2009) FcRn receptor-mediated pharmacokinetics of therapeutic IgG in the eye. Mol Vis 15:2803–2812

40. Schraermeyer U, Julien S (2012) Formation of immune complexes and thrombotic microangiopathy after intravitreal injection of bevacizumab in the primate eye. Graefes Arch Clin Exp Ophthalmol 250:1303–1313. https://doi.org/10.1007/s00417-012-2055-z

41. Taubitz T, Steinbrenner LP, Tschulakow AV et al (2016) Effects of intravitreally injected Fc fragment on rat eyes. Graefes Arch Clin Exp Ophthalmol 254:2401–2409. https://doi.org/10.1007/s00417-016-3511-y